SMi presents the launch of Cell & Gene Therapy 2018

SMi Group10 - 11 October, London, UK.
SMi introduces their inaugural event on Cell & Gene Therapy which takes place between the 10th and 11th October 2018, with an interactive pre-conference workshop on the 9th October. Cell and gene therapeutics have revolutionised modern medicine and mark a new generation in biomedical and agricultural sciences. The latest developments in cell and gene therapies and specifically in gene editing, technologies present unlimited research opportunities ranging from novel therapeutic tools to a potential revolution in the field of drug discovery.

This year's event will be led by scientists and clinicians researching, developing and testing new treatments for genetically inherited and acquired diseases using gene delivery technology, stem cell manipulation and DNA repair techniques. The conference will cover all aspects of the subject, including biomedical science principles, molecular basis of disease, current and developing technologies and clinical applications.

The conference will be inviting speakers from global pharmaceutical organisations, leading biotech companies and internationally renowned academic institutions. Expect over 16 presentations and case studies focused on the key aspects of GMP, bioprocessing, regulatory frameworks and new therapeutic developments in in the field of cell and gene.

Hear from our expert speaker panel, bringing you interesting case studies and detailed presentations on new and industry relevant topics, including:

  • Cell Therapy Research
  • Manufacturing Innovation
  • Global Medical Affairs
  • Regulatory Updates
  • GMP and Quality Control
  • Cell and Tissue Therapies (CART therapies, stem cells, cord blood, preclinical and clinical developments)
  • Regenerative Medicine
  • Advanced Therapy Production
  • Gene Therapy Development
  • Clinical Platform Development
  • Manufacturing
  • R&D of Cell and Gene Therapies

Chair for 2018

  • Pamela Tranter, Head of Translational Research Group, UCL

Key speakers include

  • Janet Glassford, Senior Quality Assessor (Biologicals), MHRA
  • Giuseppe Ronzitti, Cell and Gene Therapy Specialist, Genethon
  • Kei Kishimoto, Chief Scientific Officer, SelectaBiosciences
  • Shailesh Gupta, Senior Scientist, AstraZeneca
  • Peggy Sotiropoulou, R&D Manager, Research and Development, Celyad
  • Julie Kerby, Head of Manufacturing Development, Cell and Gene Therapy Catapult
  • Lior Raviv, Vice President, Development, Pluristem
  • Diego Aridgo, R&D Rare Disease Unit Head, Chiesi
  • Mehdi Gasmi, Chief Science and Technology Officer, Adverum Biotech
  • Emanuela Cuomo, Associate Director, Discovery Sciences, Cellular Biology Team, AstraZeneca
  • Yen Choo, Founder and Executive Chairman, Plasticell
  • Ian McKay, Innovation Lead Advanced Therapies, Innovate UK

2018 featured highlights

  • Discuss the challenges of accessing patients with commercial ATMPs
  • Understand the advantages of a risk-based approach to cell and gene therapy manufacturing
  • Hear the MHRA's perspective of UK and EU regulatory affairs regarding ATMPs
  • Explore the unique applications of the CRISPR/Cas9 system for drug development at AstraZeneca
  • Gain insight into GMP Manufacture of plasmid DNA at the NHSBT

View the full agenda online: www.cellandgeneconference.com/wpn

Early-bird rates

  • Register by 31 May and save £400
  • Register by 29th June and save £300
  • Register by 31st August and save £200

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Most Popular Now

Chemists characterize the fatal fungus among us

Life-threatening fungal infections affect more than two million people worldwide. Effective antifungal medications are very limited. Until now, one of the major challenge...

FDA approves first cancer drug through new oncolog…

The U.S. Food and Drug Administration today approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopa...

Discovery of kidney cancer driver could lead to ne…

University of North Carolina Lineberger Comprehensive Cancer Center scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic...

The immune system: T cells are built for speed

Without T cells, we could not survive. They are a key component of our immune system and have highly sensitive receptors on their surface that can detect pathogens. The e...

FDA approves first targeted treatment for patients…

The U.S. Food and Drug Administration today approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (...

Women and older people under-represented in drug t…

Trying to determine how best to treat a patient, doctors often look to randomized clinical trials to guide their choice of what drug to prescribe. One of the most common ...

Novartis renews drug donation of Egaten® (triclabe…

Novartis reaffirms its commitment to the fight against liver fluke (fascioliasis), signing a renewed memorandum of understanding with the World Health Organization (WHO) ...

Pfizer initiates pivotal Phase 3 program for inves…

Pfizer Inc. (NYSE:PFE) and Spark Therapeutics (NASDAQ:ONCE) announced today that Pfizer initiated a Phase 3 open-label, multi-center, lead-in study (NCT03587116) to evalu...

Sanofi and REVOLUTION Medicines launch global part…

Sanofi and REVOLUTION Medicines, Inc. today announced an exclusive worldwide partnership to develop and commercialize targeted therapies, based on the biology of the cell...

Novartis marks a new era for migraine patients wit…

Novartis announced today that the European Commission (EC) approved Aimovig® (erenumab) for the prevention of migraine in adults experiencing four or more migraine days p...

FDA grants Breakthrough Therapy Designation for Ro…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq® (atezolizumab) i...

New findings suggest allergic responses may protec…

The components of the immune system that trigger allergic reactions may also help protect the skin against cancer, suggest new findings. The research, led by Imperial Col...